Literature DB >> 3102395

Prospective microbiologic surveillance in control of nosocomial methicillin-resistant Staphylococcus aureus.

T J Walsh, D Vlahov, S L Hansen, E Sonnenberg, R Khabbaz, T Gadacz, H C Standiford.   

Abstract

A prospective microbiological surveillance (PMS) program was developed in a comprehensive hospital-wide effort for control of nosocomial methicillin-resistant Staphylococcus aureus (MRSA). This PMS program entailed: active identification of colonized and infected patients; application of a screening microbiologic system for MRSA; isolation of colonized and infected patients; antibiotic decolonization of MRSA; and educational efforts. The PMS program was studied over three and one half years for its contribution to infection control of MRSA, early identification of nosocomial MRSA outbreaks, use of the highest yield surveillance culture sites, and cost effectiveness. Following initiation of the PMS program in December 1982, during an MRSA outbreak, the frequency of new MRSA cases declined from 14 to none by the end of a 3-month pilot study. The frequency of new MRSA cases stabilized at approximately 2 per month until October 1983, when the PMS system allowed prompt detection of a new outbreak of 11 cases. Following isolation and antibiotic decolonization, the frequency of cases again declined to 3 per month. A third outbreak in December 1985 again was promptly detected and controlled. Infection to colonization ratio decreased from a maximum of 1.5 during outbreaks to a minimum of 0.17 after outbreaks. Wounds and tracheostomy sites provided the greatest yield of detection of new cases of MRSA. During one 15-month period, 35 of the 43 new cases were detected initially at wounds and tracheostomy sites. No new MRSA cases were detected by a positive axillary or nares site alone. The estimated quarterly cost of outbreaks and infection paralleled the quarterly frequency of new MRSA cases.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3102395     DOI: 10.1017/s0195941700066923

Source DB:  PubMed          Journal:  Infect Control        ISSN: 0195-9417


  7 in total

Review 1.  MRSA and the environment: implications for comprehensive control measures.

Authors:  N Cimolai
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-02-14       Impact factor: 3.267

2.  Molecular characterization of epidemic ciprofloxacin- and methicillin-resistant Staphylococcus aureus strains colonizing patients in an intensive care unit.

Authors:  E E Udo; I A al-Obaid; L E Jacob; T D Chugh
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

3.  Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome.

Authors:  T J Walsh; H C Standiford; A C Reboli; J F John; M E Mulligan; B S Ribner; J Z Montgomerie; M B Goetz; C G Mayhall; D Rimland
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

4.  Diversity and stability of restriction enzyme profiles of plasmid DNA from methicillin-resistant Staphylococcus aureus.

Authors:  A J Zuccarelli; I Roy; G P Harding; J J Couperus
Journal:  J Clin Microbiol       Date:  1990-01       Impact factor: 5.948

5.  The management of infection and colonization due to methicillin-resistant Staphylococcus aureus: A CIDS/CAMM position paper.

Authors:  Andrew E Simor; Mark Loeb
Journal:  Can J Infect Dis       Date:  2004-01

6.  Combined topical and oral antimicrobial therapy for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) colonization in hospitalized patients.

Authors:  Scott K Fung; Marie Louie; Andrew E Simor
Journal:  Can J Infect Dis       Date:  2002-09

7.  Methicillin-resistant Staphylococcus aureus: A public health issue with economic consequences.

Authors:  Mireille Goetghebeur; Pierre-Alexandre Landry; Donald Han; Colin Vicente
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-01       Impact factor: 2.471

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.